TY - JOUR
T1 - Cardiovascular effects of polymethylmethacrylate use in percutaneous vertebroplasty
AU - Kaufmann, Timothy J.
AU - Jensen, Mary E.
AU - Ford, Gabriele
AU - Gill, Lena L.
AU - Marx, William F.
AU - Kallmes, David F.
PY - 2002
Y1 - 2002
N2 - BACKGROUND AND PURPOSE: Previous investigators have described an association between polymethylmethacrylate (PMMA) use in hip arthroplasty and cardiovascular derangement. Our purpose was to evaluate the effects of PMMA injection on patient vital signs during percutaneous vertebroplasty. METHODS: We retrospectively reviewed patient charts at our institution to gather blood pressure, heart rate, and arterial oxygen saturation data for the following time points: before, during, 5 minutes after, and 10 minutes after PMMA injection during percutaneous vertebroplasty. These data were obtained for 142 injections (78 patients), and preinjection vital signs were compared with vital signs during and after PMMA injection. Multivariable regression modeling was used to ascertain the effects of cardiopulmonary comorbidities on vital signs. RESULTS: Mean arterial blood pressure and heart rate during, 5 minutes after, and 10 minutes after PMMA injection were not significantly different from their respective preprocedure values (P = .19-.92). Values for oxygen saturation during PMMA injection and 5 minutes thereafter were not significantly different from preprocedure values (P = .80 and .89, respectively). Oxygen saturation was significantly lower at 10 minutes after injection than before injection (P = .007), although the mean difference was negligible (0.6%). CONCLUSION: We find no generalized association between PMMA injection during percutaneous vertebroplasty and systemic cardiovascular derangement.
AB - BACKGROUND AND PURPOSE: Previous investigators have described an association between polymethylmethacrylate (PMMA) use in hip arthroplasty and cardiovascular derangement. Our purpose was to evaluate the effects of PMMA injection on patient vital signs during percutaneous vertebroplasty. METHODS: We retrospectively reviewed patient charts at our institution to gather blood pressure, heart rate, and arterial oxygen saturation data for the following time points: before, during, 5 minutes after, and 10 minutes after PMMA injection during percutaneous vertebroplasty. These data were obtained for 142 injections (78 patients), and preinjection vital signs were compared with vital signs during and after PMMA injection. Multivariable regression modeling was used to ascertain the effects of cardiopulmonary comorbidities on vital signs. RESULTS: Mean arterial blood pressure and heart rate during, 5 minutes after, and 10 minutes after PMMA injection were not significantly different from their respective preprocedure values (P = .19-.92). Values for oxygen saturation during PMMA injection and 5 minutes thereafter were not significantly different from preprocedure values (P = .80 and .89, respectively). Oxygen saturation was significantly lower at 10 minutes after injection than before injection (P = .007), although the mean difference was negligible (0.6%). CONCLUSION: We find no generalized association between PMMA injection during percutaneous vertebroplasty and systemic cardiovascular derangement.
UR - http://www.scopus.com/inward/record.url?scp=0036123590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036123590&partnerID=8YFLogxK
M3 - Article
C2 - 11950651
AN - SCOPUS:0036123590
SN - 0195-6108
VL - 23
SP - 601
EP - 604
JO - American Journal of Neuroradiology
JF - American Journal of Neuroradiology
IS - 4
ER -